AVALO THERAPEUTICS INC

Avalo Therapeutics’ stock plunge exposes the high‑risk reality of precision medicine, revealing weak earnings, volatile pricing, and the critical need for a solid pipeline to succeed in the pharma market.

Avalo Therapeutics, a clinical-stage precision medicine company, is facing market challenges, including a significant stock price decline, but remains committed to developing innovative treatments for patients with unmet clinical needs.